Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, announced long-term preclinical efficacy data... read more
Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, announced long-term preclinical efficacy data... read more
On April 13, 2018 the 4th U.S. Circuit Court of Appeals struck down a Maryland law that allowed the state attorney general to sue drugmakers who raised prices on generic or off-patent drugs by... read more
Biogen (Nasdaq: BIIB) and Neurimmune announced today that Biogen has exercised its option to further reduce the previously negotiated royalty rates payable on potential future sales of aducanumab... read more
Gilead Sciences, Inc. (Nasdaq: GILD) and Verily Life Sciences LLC, an Alphabet company, today announced a scientific collaboration using Verily’s Immunoscape platform to identify and better... read more
On April 19th an FDA advisory committee voted unanimously to recommend approval of the first prescription cannabidiol medicine — to treat rare and severe forms of epilepsy. The drug is known as... read more